Overview
- At 36 weeks, 27.1% of patients on the combination achieved complete skin clearance with at least 10% weight loss versus 5.8% on Taltz alone, meeting the primary endpoint.
- In a separate late-stage study, 31.7% on the combination reached at least a 50% reduction in psoriatic arthritis activity plus at least 10% weight loss versus 0.8% with Taltz alone.
- The late-stage program enrolled 274 adults with moderate-to-severe plaque psoriasis and overweight or obesity, and nearly all had disease in sensitive areas such as the face, scalp, or genitals.
- Lilly reported adverse events were generally mild to moderate, with full data to be submitted for peer-reviewed publication and regulatory review.
- The company said about 61% of U.S. patients with psoriasis are overweight or obese with at least one weight-related comorbidity, highlighting the potential value of a dual-focus therapy.